Loading
institutionsInstitution
HL7 International
The standards body behind FHIR, the healthcare data interface now used to pull oncology records into trials, registries and AI tools, and home of the mCODE cancer data standard.
Also called: Health Level SevenHL7FHIR
Overview
Founded in 1987, Health Level Seven International develops the messaging and data standards that let health IT systems exchange information, including HL7 v2, CDA and, since 2011, Fast Healthcare Interoperability Resources (FHIR), which US regulation now requires electronic health record vendors to support. For oncology, the minimal Common Oncology Data Elements (mCODE) implementation guide developed with ASCO's CodeX accelerator defines a core set of structured cancer data (diagnosis, staging, biomarkers, treatments, outcomes) so that records can feed registries, trial matching, real-world evidence and quality measurement without manual abstraction. HL7's work groups also cover genomics reporting and patient-reported outcomes.
Location
Ann Arbor, MI, US
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#399 · 14 points (0 Newsweek + 0 NCI + 14 from 7 linked objects) · ranking
- FHIR standard
- mCODE oncology data standard (with ASCO CodeX)
- Genomics reporting implementation guide
- HL7 v2 and CDA
Similar pages
- IdeaSimulate eligibility against real-world data before every protocol is locked
Shares AI trial matching & clinical decision support, Real-world evidence, Weak real-world evidence and registries, Trials enrol too few, too slowly.
- IdeaNo mCODE, no payment: tie oncology reimbursement to a minimal structured record
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
- IdeaJust-in-time site activation: open a site in two weeks when a patient appears
Shares AI trial matching & clinical decision support, American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
- IdeaOpen, benchmarked algorithms for lines of therapy and progression from routine data
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
- IdeaPoint-of-care randomisation built into the oncology record
Shares Real-world evidence, Trials enrol too few, too slowly, Data silos.
- IdeaEvery payer covers routine care costs for trial participants, in every country
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaLay trial navigators funded per centre, evaluated in a randomised trial
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaStop excluding people with a prior cancer, controlled HIV, or treated hepatitis
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly, National Cancer Institute (NIH).